leadf
logo-loader
viewAntibe Therapeutics Inc

Full interview: Antibe Therapeutics finishes Phase 2 trial for ATB-346; results expected in weeks

Antibe Therapeutics (CVE: ATE OTCQB: ATBPF) CEO Dan Legault joined Steve Darling from Proactive Vancouver to share details about how the company is dealing with the Pandemic crisis and if they are seeing any effect on their Phase 2 study with their lead drug, ATB-346. Legault also told Proactive about their other drug, this one for post-surgery pain, ATB-352 and what the next steps are in its development

Quick facts: Antibe Therapeutics Inc

Price: 0.335 CAD

TSX-V:ATE
Market: TSX-V
Market Cap: $129.13 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Antibe Therapeutics releases data from company’s Phase II placebo-controlled...

Antibe Therapeutics (CVE: ATE) CEO Dan Legault joined Steve Darling from Proactive Vancouver with new results from the company’s analysis of primary and secondary data from ATB-346’s recent placebo-controlled efficacy trial. Legault shares the data with Proactive and he also maps out the...

on 08/12/2020

2 min read